Strong quarter masking structural margin pressure

Volume growth only 3.8% YoY (13.5k vs 13k tonnes), revenue +34.4% → confirms price-led

Delivered 10.14% EBITDA margin, OPM 10.1% — matches claim

Isostearic only 4% of Q1 revenue; entry barriers acknowledged (cosmetics approvals ongoing)

Current 60%, targeting 70-75% by FY27 end = 10-15 pp, realistic within current capacity

MD admitted 'might remain sustainable, might not — business risk'; realization +30% YoY but geopolitical

Current export contribution only 7-8%, unchanged; long-term goal 50% — early innings, no progress this quarter

Realization +30% vs Q1 FY26 (+25% vs Q4 FY26); supply constraints + dumping drop enabled price pass-through; marked shift from prior weakness

60% now vs 35-40% prior (per management); Q1 delivery shows 13.5K tonnes vs 13K prior, modest but moving

Longer gestation than expected due to cosmetics entry barriers (Europe/Japan strict); still at 4% revenue after 2 years; no material commercial traction

Still 7-8% of revenue despite FTA tailwinds; dimer + isostearic are targets but execution lagging; 50% long-term goal still distant

No change; management calls itself 'too small to lobby'; 9% margin drag remains unaddressed structural issue

Yes, looking at current situation, we feel we will be able to maintain.

In next 1-2 years, we will reach more than 80% capacity utilization.

Energy conservation reducing power consumption 30%+, solid fuel 35%+; time-motion studies; catalyst/consumable optimization underway.

Yes, fairly large number. Around 7 to 8 big customers.

Inverted duty structure (22.5% raw material, 7.5% finished product) is the basic reason. R&D spend ~50 lakhs recurring, 1-1.5% of sales as of now.

Isostearic introduced 2 years ago, still ramping due to entry barriers in cosmetics; next quarter new oleochemical product launching.

We won't like to share customer names or quantities sold.

Geopolitical supply chain issue (Middle East crisis); imports reduced; that allowed price pass-on.

If dumping starts again, we cannot do anything about it. But we are not doing crazy expansion, not taking debt.

Linoleic 40% of volume goes to paint as crude substitute. Growth is being driven by pricing, not volume.

Yes, customer trials ongoing. Better than commodity; magnitude once we enter contract.

Not EV battery. Other oleochemical product. We won't diverge on application.

Better than current.

Finished product 7.5%, raw material 16.5%, differential 9% is margin lost in this process.

Might remain sustainable, might not. This is a business risk. That's why we're not expanding aggressively or taking debt.

Realization from Q4 up 25%, from Q1 FY26 up 30%.

Yes, we hope so.

Yes, that's correct. From March onwards, margins have improved. We are happy with realization.

First step is to reach 100% capacity utilization, then we will ramp up capacity.

At couple of companies finished all 5 steps; at couple at 4th step; everywhere crossed 3rd step.

Yes.

Our process is different. We follow Green process. That is our USP and reason stability tests take longer.

I would not enter any long-term contract with so much volatility. No company commits on quantity without committing price.

Quantities are going down; prices are going up.

Every quarter we intend to grow by 5-7%. By end of 4th quarter, we would have grown by 15-20%. This is on quantity.

We would like to increase sales volume because that's more sustainable. We are okay with current margin level.

Quantity-based growth targeting; capacity at 60%, room to grow to 70-75%; assumes no major dumping resumption

Multi-year goal; dimer + isostearic focus; India-UK/EU FTA tailwinds; no timeline or interim milestones

Dependent on continued lower imports + Chinese dumping staying suppressed; management candid this is 'business risk'

Already at 10.1% in Q1, tracking prior guidance; no major beat expected

Trial run to start, ramp post-stabilization; margins expected better than current; product kept confidential

Disciplined capital allocation; management explicitly cautious on sustainability

Current margin expansion entirely driven by reduced Chinese dumping + supply constraints. If either reverses, margins collapse. Management admitted 'business risk', won't enter long-term contracts.

Raw material duty 16.5%, finished product 7.5%, 9% differential is lost margin. Reduced from 27.5% in 2024 but still material. Management calls itself 'too small to lobby' and has made no representations.

Isostearic only 4% revenue after 2 years; cosmetics approval barriers (Europe, Japan strict); management gave 'yes' to whether outcome by FY27 end but no specific volume target. Long gestation creates execution risk.

40% of revenue from paint industry as linoleic is crude derivative substitute. No plan to reduce dependence. Paint sector downturn directly hits revenue. Management candid: 'We don't intend to reduce our dependence.'

40K MT oleochemical capacity launching Q2 FY27; product application kept confidential due to customer confidentiality; margins promised 'better than current' (10.1%) but unproven. Trial run to ramp means execution risk.